Andrea Montes-Torres1,2, Gloria Aparicio3, Raquel Rivera4, Eva Vilarrasa5, María Marcellán6, Jaume Notario7, Caridad Soria8, Isabel Belinchón9, Pablo de la Cueva10, Marta Ferrán11, Jose Manuel Carrascosa12, Francisco J Gómez13, Laura Salgado14, Manuel Velasco15, Miguel Ángel Descalzo16, Ignacio García-Doval16,17, Esteban Daudén1. 1. a Department of Dermatology , Hospital Universitario de La Princesa , Madrid , Spain. 2. b Department of Dermatology , Hospital Central de la Defensa Gómez Ulla , Madrid , Spain. 3. c Department of Dermatology , Hospital Universitario Vall d'Hebron , Barcelona , Spain. 4. d Department of Dermatology , Hospital Universitario Doce de Octubre , Madrid , Spain. 5. e Department of Dermatology , Hospital Universitario de la Santa Creu i Sant Pau , Barcelona , Spain. 6. f Department of Dermatology , Hospital Universitario Marqués de Valdecilla , Santander , Spain. 7. g Department of Dermatology , Hospital Universitario de Bellvitge , L'Hospitalet de Llobregat , Spain. 8. h Department of Dermatology , Hospital General Universitario Reina Sofía , Murcia , Spain. 9. i Department of Dermatology , Hospital General Universitario de Alicante , Alicante , Spain. 10. j Department of Dermatology , Hospital Universitario Infanta Leonor , Madrid , Spain. 11. k Department of Dermatology , Hospital del Mar, Parc de Salut Mar , Barcelona , Spain. 12. l Department of Dermatology , Hospital Universitario Germans Trias i Pujol , Badalona , Spain. 13. m Department of Dermatology , Hospital Universitario Reina Sofía , Córdoba , Spain. 14. n Department of Dermatology , Complejo Hospitalario Universitario de Pontevedra , Pontevedra , Spain. 15. o Department of Dermatology , Hospital Universitario Arnau de Vilanova , Valencia , Spain. 16. p Research Unit. Fundación Piel Sana AEDV , Madrid , Spain. 17. q Department of Dermatology , Complejo Hospitalario Universitario de Vigo , Vigo , Spain.
Abstract
Background: The management of HIV-positive patients with psoriasis is controversial and limited to individual cases or short series of patients. Objectives: To evaluate the safety and effectiveness of conventional and biologic immunosuppressive drugs in the treatment of patients with psoriasis and concomitant HIV infection. Methods: A retrospective multicenter study was conducted. The study included data from 2008 to 2016. Inclusion criteria were: HIV adult patients with moderate-to-severe psoriasis, HIV viral load determinations at baseline and at least after 6 months of treatment, and systemic immunosuppressive treatment for at least 6 months. A descriptive analysis was performed. Results: Twenty-three patients with plaque-type psoriasis and HIV infection (five with AIDS) were included. Median follow-up time was 3.2 years. The main drugs used were etanercept, methotrexate, and ustekinumab. In most cases, viral load and CD4 cell count not only remained stable but also improved throughout the follow-up. Six patients presented severe adverse events during the follow-up, four of them in the AIDS stage. At the end of the follow-up period, 76.5% of the patients had achieved a PASI 75. Conclusion: Biologic drugs, both anti-TNF alpha agents and ustekinumab, seem to have an acceptable safety profile and high effectiveness in HIV-positive patients.
Background: The management of HIV-positivepatients with psoriasis is controversial and limited to individual cases or short series of patients. Objectives: To evaluate the safety and effectiveness of conventional and biologic immunosuppressive drugs in the treatment of patients with psoriasis and concomitant HIV infection. Methods: A retrospective multicenter study was conducted. The study included data from 2008 to 2016. Inclusion criteria were: HIV adult patients with moderate-to-severe psoriasis, HIV viral load determinations at baseline and at least after 6 months of treatment, and systemic immunosuppressive treatment for at least 6 months. A descriptive analysis was performed. Results: Twenty-three patients with plaque-type psoriasis and HIV infection (five with AIDS) were included. Median follow-up time was 3.2 years. The main drugs used were etanercept, methotrexate, and ustekinumab. In most cases, viral load and CD4 cell count not only remained stable but also improved throughout the follow-up. Six patients presented severe adverse events during the follow-up, four of them in the AIDS stage. At the end of the follow-up period, 76.5% of the patients had achieved a PASI 75. Conclusion: Biologic drugs, both anti-TNF alpha agents and ustekinumab, seem to have an acceptable safety profile and high effectiveness in HIV-positivepatients.
Authors: Julie J Hong; Edward K Hadeler; Megan L Mosca; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2022-01-12
Authors: Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri Journal: Biomedicines Date: 2022-01-21
Authors: Jennifer Beecker; Curtis Cooper; Mark G Kirchhof; Anton L Pozniak; Juergen K Rockstroh; Kim A Papp; Jan P Dutz; Melinda J Gooderham; Robert Gniadecki; Chih-Ho Hong; Charles W Lynde; Catherine Maari; Yves Poulin; Ronald B Vender; Sharon L Walmsley Journal: Dermatol Ther (Heidelb) Date: 2022-04-21